NAMGEM
COMPOSITION : Each Softl Gelatin Capsule contains :  Natural Micronized Progesterone 100 mg/200 mg 

INDICATIONS
Primary & Secondary amenorrhoea  Threatened & recurrent abortions  HRT in pre & post menopause In Vitro Fertilization (IVF) Benign mastopathy Infertility Dysfunctional uterine bleeding 

INDICATIONS WITH DOSAGE

Maintenance of Pregnancy in cases of Threatend / Recurrent abortion - 200 to 400 mg per day in divided doses.
Sterility due to luteal deficiency : 400 mg to 600 mg per day upto the 12th week of pregnancy.
Treatment of Purperal depression : 400 mg twice daily in divided doses.
Benign mastopathies : 200-300 mg for 10 days in a month, usually from 17th to 26th day of Monthly cycle.
Benign mastopathies-Development of non cacerous/non malignant cells in breast.
Secondary amenorrhoea : Single daily dose of 400 mg in the evening for 10 days.
(Amenorrhoea-Abnormal absence of menstruation)
Premenstrual syndrome : 200 to 400 mg 1-2 times daily from 12th to 14th day of cycle until onset of menstruation.
Oocyte donation programme : 100 mg twice daily from the day of transfer till pregnancy is confirmed. This may be increased to a maximum of 600 mg/ day and continued upto 12th week of pregnancy.
The menopause to reduce the risk of Endometrial Hyperplasia : 200 mg orally to post menopausal women with a uterus who are receiving daily conjugated estrogen Tablets 
Dysfunctional uterine bleeding: 200-300 mg per day in divided dosage till bleeding stop
 
DOSAGE
Maintenance of Pregnancy:The recommended dose is twice weekly or more frequent (max. daily) injection of 25-100 mg from approximately day 15 or day of ovum puck up onwards until 12-14 weeks of pregnancy when secretion of progesterone from placenta is generally well established.
Threatened Abortion: In Critical Patients the recommended dose is 200 mg daily for patients who have improved cliniclly on 200 mg daliy dose can be reduced to 100 mg daily. 
Dysfunctional uterine bleeding: The recommended dose is 50-100 mg daily given for five to ten consecutive days until 2 days before anticipated onset of menstruation.
 
Indications:

Vaginal / Rectal Supplementation of NAMGEM during the luteal phase in case of sterility due to luteal deficiency and during ART and IUI procedures Treatment of puerperal depression. Treatment of threatened / recurrent abortion (to help pregnancy) in case of proven luteal deficiency.

Oral NAMGEM
Disorders associated with deficiency of progesterone, in particular: Premenstrual syndrome Dysfunctional uterine bleeding and other menstrual irregularities through dysovulation or anovulation Secondary amenorrhea: As progesterone challenge test followed by cyclical therapy along with estrogen if required. Benign mastopathy
  
Perimenopause:
As hormone replacement therapy either alone (when endogenous estrogen is present) or as a complement to estrogen therapy to significantly reduce the risk of endometrial hyperplasia and endometrial carcinoma, In case of side effects with oral route of administration (such as drowsiness) or in case of severe hepatic disease, an alternative vaginal route of administration is recommended.

Pregnancy & Lactation:
Use of NAMGEM during pregnancy is reserved to the first trimester and to the vaginal tract.
Administration of Micronised progesterone during the second and third trimester of pregnancy may result in the appearance of a severe cholestasis or hepatitis. It is not a treatment against the risks of premature labour pains.

Side Effects:
The menstrual cycle may be shortened or there may be inter-menstrual bleeding. Menstruation may occur earlier then expected or, more rarely, menstruation may be delayed. After administration by the oral route, drowsiness or giddiness, arising 1 to 3 hours after ingestion of the product has been reported.
Soreness, diarrhoea and flatulence may occur after rectal administration of the drug. As with other vaginal and rectal preparations. some leakage of the capsule base may occur.